Acquired Company

ARS Pharmaceuticals closed its merger with Silverback Therapeutics, Inc. on November 8, 2022, with the combined company to operate as ARS Pharmaceuticals, Inc. and shares of its common stock to commence trading under the SPRY symbol on November 9, 2022.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California. Show more

11682 El Camino Real, San Diego, CA, 92130, United States

https://ars-pharma.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

910.4M

52 Wk Range

$6.66 - $18.90

Previous Close

$9.21

Open

$9.18

Volume

677,834

Day Range

$9.04 - $9.33

Enterprise Value

777.5M

Cash

288.2M

Avg Qtr Burn

-47.05M

Insider Ownership

17.46%

Institutional Own.

91.05%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
neffy® (epinephrine nasal spray) Details Acute flares in patients with chronic spontaneous urticaria	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SBT6050 (TLR8 Agonist) Details Cancer, Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.